Egypt: EDA Introduces a Unified Registration Approach for Medical Devices with Composition Differences

Regulatory Update | August 2026

The Egyptian Drug Authority (EDA) has introduced a new registration approach that allows certain medical devices with differences in composition data but the same intended use, medical purpose, classification, and basic design to be registered under a single, unified technical file.

Issued by the EDA's Central Administration for Medical Devices on 13 August 2026, the notice gives manufacturers a clearer framework for grouping eligible device codes or models together, rather than treating every composition variation as a separate registration.

What Has Changed?

Under the new approach, medical devices with differing composition data can be submitted within one unified technical registration file as long as the following core characteristics remain identical across all included models:

• Intended use

• Medical purpose

• Regulatory classification

• Basic design

In other words, composition differences no longer automatically require a separate technical file, provided the device's fundamental identity stays the same.

Why This Matters for Manufacturers

Most medical-device portfolios include multiple models or codes that serve the same function but vary slightly in materials or raw-material composition. Previously, these variations often meant extra documentation and separate submissions even when the products were functionally identical.

The EDA's new approach simplifies this by allowing eligible variations to be consolidated into one file. But consolidation isn't automatic: eligibility depends entirely on meeting the four conditions above.

Four Conditions to Meet

1. Same intended use

Any variation that changes the device's purpose or application falls outside this pathway and requires separate regulatory assessment.

2. Same medical purpose

The medical function must stay consistent this approach is for variations within a device family, not for fundamentally different products.

3. Same classification

Manufacturers should confirm the classification of each code or model before structuring a combined submission.

4. Same basic design

Composition changes cannot be considered independently of the device's core design if the design changes, the pathway no longer applies.

What Manufacturers Should Prepare

A unified technical file still requires full transparency on how included models differ. Manufacturers should be ready to clearly document:

• Which device codes or models are included

• How their composition differs

• Confirmation that intended use, medical purpose, classification, and basic design are unchanged

Consolidation reduces duplication it doesn't reduce the level of technical detail required.

What This Approach Is Not

This is not a blanket mechanism for merging all variants of a device. Based on available information, it applies specifically to new registration applications and does not retroactively change the status of devices already registered. Each product portfolio and registration scenario should be assessed individually.

Part of a Broader Regulatory Shift in Egypt

This notice builds on other recent changes to Egypt's medical-device framework. In April 2026, for example, the EDA introduced facilitations for locally manufactured devices holding CE certification, allowing eligible manufacturers to submit registration or re-registration files without certain supporting documents (such as Free Sale Certificates, stability studies, or biocompatibility reports) subject to the EDA's discretion to request them when necessary.

Together, these updates reflect a regulatory environment that is becoming more structured and more nuanced around different product configurations and registration pathways.

ARQon Regulatory Insight

For manufacturers with multiple device codes or models sharing the same core characteristics, this notice offers a real strategic opportunity not just administrative simplification.

The real value lies in using this pathway to structure a smarter registration strategy: clearly identifying where composition differences exist, while confirming the device's fundamental regulatory identity remains intact.

A structured portfolio review before submission can help determine:

Which products can be grouped → What differences must be documented → Which pathway applies → What documentation is required.

What Manufacturers Should Do Now

1. Review your product portfolio: identify models with composition differences but shared intended use and medical purpose.

2. Compare technical characteristics: confirm classification and basic design are unchanged.

3. Assess your technical file strategy: determine which products qualify for a unified file.

4. Prepare clear documentation: identify each code/model and its composition differences.

5. Confirm current EDA requirements: verify eligibility against the latest procedures before submitting.

Key Takeaway

Egypt's August 2026 notice gives manufacturers a more defined path to registering medical devices with composition differences under one technical file provided intended use, medical purpose, classification, and basic design remain unchanged. For companies with multi-model portfolios, understanding this pathway early can lead to a faster, more efficient Egypt market-entry strategy.

Regulatory changes are rarely just about compliance they can directly shape how efficiently a product portfolio enters a market.

How ARQon Can Support You

• Regulatory intelligence and monitoring

• Egypt market-entry strategy

• Medical-device registration planning

• Technical-file and documentation gap assessment

• Product portfolio regulatory assessment

• Regulatory pathway analysis

• Cross-border market-access strategy

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.